186 related articles for article (PubMed ID: 25343529)
21. Receptor mechanisms in the treatment of schizophrenia.
Reynolds GP
J Psychopharmacol; 2004 Sep; 18(3):340-5. PubMed ID: 15358977
[TBL] [Abstract][Full Text] [Related]
22. Synthesis and biological investigation of new equatorial (β) stereoisomers of 3-aminotropane arylamides with atypical antipsychotic profile.
Stefanowicz J; Słowiński T; Wróbel MZ; Herold F; Gomółka AE; Wesołowska A; Jastrzębska-Więsek M; Partyka A; Andres-Mach M; Czuczwar SJ; Łuszczki JJ; Zagaja M; Siwek A; Nowak G; Żołnierek M; Bączek T; Ulenberg S; Belka M; Turło J
Bioorg Med Chem; 2016 Sep; 24(18):3994-4007. PubMed ID: 27377863
[TBL] [Abstract][Full Text] [Related]
23. Ziprasidone (CP-88,059): a new antipsychotic with combined dopamine and serotonin receptor antagonist activity.
Seeger TF; Seymour PA; Schmidt AW; Zorn SH; Schulz DW; Lebel LA; McLean S; Guanowsky V; Howard HR; Lowe JA
J Pharmacol Exp Ther; 1995 Oct; 275(1):101-13. PubMed ID: 7562537
[TBL] [Abstract][Full Text] [Related]
24. Pharmacological profile of lurasidone, a novel antipsychotic agent with potent 5-hydroxytryptamine 7 (5-HT7) and 5-HT1A receptor activity.
Ishibashi T; Horisawa T; Tokuda K; Ishiyama T; Ogasa M; Tagashira R; Matsumoto K; Nishikawa H; Ueda Y; Toma S; Oki H; Tanno N; Saji I; Ito A; Ohno Y; Nakamura M
J Pharmacol Exp Ther; 2010 Jul; 334(1):171-81. PubMed ID: 20404009
[TBL] [Abstract][Full Text] [Related]
25. Aripiprazole, a novel antipsychotic drug, preferentially increases dopamine release in the prefrontal cortex and hippocampus in rat brain.
Li Z; Ichikawa J; Dai J; Meltzer HY
Eur J Pharmacol; 2004 Jun; 493(1-3):75-83. PubMed ID: 15189766
[TBL] [Abstract][Full Text] [Related]
26. 5-HT1A and 5-HT7 receptors contribute to lurasidone-induced dopamine efflux.
Huang M; Horiguchi M; Felix AR; Meltzer HY
Neuroreport; 2012 May; 23(7):436-40. PubMed ID: 22415605
[TBL] [Abstract][Full Text] [Related]
27. Synthesis and binding affinity of potential atypical antipsychotics with the tetrahydroquinazolinone motif.
Carro L; Raviña E; Domínguez E; Brea J; Loza MI; Masaguer CF
Bioorg Med Chem Lett; 2009 Nov; 19(21):6059-62. PubMed ID: 19796944
[TBL] [Abstract][Full Text] [Related]
28. Synthesis and pharmacological evaluation of potent and highly selective D3 receptor ligands: inhibition of cocaine-seeking behavior and the role of dopamine D3/D2 receptors.
Campiani G; Butini S; Trotta F; Fattorusso C; Catalanotti B; Aiello F; Gemma S; Nacci V; Novellino E; Stark JA; Cagnotto A; Fumagalli E; Carnovali F; Cervo L; Mennini T
J Med Chem; 2003 Aug; 46(18):3822-39. PubMed ID: 12930145
[TBL] [Abstract][Full Text] [Related]
29. Long-term effects of JL 13, a potential atypical antipsychotic, on rat dopamine and serotonin receptor subtypes.
Moran-Gates T; Massari C; Graulich A; Liégeois JF; Tarazi FI
J Neurosci Res; 2006 Aug; 84(3):675-82. PubMed ID: 16810690
[TBL] [Abstract][Full Text] [Related]
30. Continuation of structure-activity relationship study of novel benzamide derivatives as potential antipsychotics.
Xu M; Guo S; Yang F; Wang Y; Wu C; Jiang X; Zhao Q; Chen W; Tian G; Zhu F; Xie Y; Hu T; Wang Z; He Y; Shen J
Arch Pharm (Weinheim); 2019 Apr; 352(4):e1800306. PubMed ID: 30702760
[TBL] [Abstract][Full Text] [Related]
31. Novel pharmacological approaches to the treatment of schizophrenia.
Fink-Jensen A
Dan Med Bull; 2000 Jun; 47(3):151-67. PubMed ID: 10913983
[TBL] [Abstract][Full Text] [Related]
32. The importance of 5-HT1A receptor agonism in antipsychotic drug action: rationale and perspectives.
Newman-Tancredi A
Curr Opin Investig Drugs; 2010 Jul; 11(7):802-12. PubMed ID: 20571976
[TBL] [Abstract][Full Text] [Related]
33. Synthesis and evaluation of a series of piperidine-2,6-dione-piperazine (piperidine) derivatives as multireceptor atypical antipsychotics.
Chen Y; Xu X; Liu X; Liu BF; Zhang G
Arch Pharm (Weinheim); 2012 Nov; 345(11):859-69. PubMed ID: 22886598
[TBL] [Abstract][Full Text] [Related]
34. Design, Synthesis and Biological Investigation of Flavone Derivatives as Potential Multi-Receptor Atypical Antipsychotics.
Gao L; Yang Z; Xiong J; Hao C; Ma R; Liu X; Liu BF; Jin J; Zhang G; Chen Y
Molecules; 2020 Sep; 25(18):. PubMed ID: 32911828
[TBL] [Abstract][Full Text] [Related]
35. Lurasidone (SM-13496), a novel atypical antipsychotic drug, reverses MK-801-induced impairment of learning and memory in the rat passive-avoidance test.
Ishiyama T; Tokuda K; Ishibashi T; Ito A; Toma S; Ohno Y
Eur J Pharmacol; 2007 Oct; 572(2-3):160-70. PubMed ID: 17662268
[TBL] [Abstract][Full Text] [Related]
36. Studies towards the identification of a new generation of atypical antipsychotic agents.
Garzya V; Forbes IT; Gribble AD; Hadley MS; Lightfoot AP; Payne AH; Smith AB; Douglas SE; Cooper DG; Stansfield IG; Meeson M; Dodds EE; Jones DN; Wood M; Reavill C; Scorer CA; Worby A; Riley G; Eddershaw P; Ioannou C; Donati D; Hagan JJ; Ratti EA
Bioorg Med Chem Lett; 2007 Jan; 17(2):400-5. PubMed ID: 17084080
[TBL] [Abstract][Full Text] [Related]
37. In-vivo effects of the 1,2,4-piperazine derivatives MM5 and MC1, putative 5-HT agonists, on dopamine and serotonin release in rat prefrontal cortex.
Iskra-Jopa J; Gołembiowska K; Dziubina A; Cybulski M; Duszyńska B; Chilmonczyk Z
J Pharm Pharmacol; 2005 Feb; 57(2):205-11. PubMed ID: 15720784
[TBL] [Abstract][Full Text] [Related]
38. Synthesis and Biological Evaluation of Five-Atom-Linker-Based Arylpiperazine Derivatives with an Atypical Antipsychotic Profile.
Wu C; Wang Y; Yang F; Shi W; Wang Z; He L; He Y; Shen J
ChemMedChem; 2019 Dec; 14(24):2042-2051. PubMed ID: 31746558
[TBL] [Abstract][Full Text] [Related]
39. A search for colocalization of serotonin 5-HT2A and 5-HT1A receptors in the rat medial prefrontal and entorhinal cortices--immunohistochemical studies.
Wedzony K; Chocyk A; Maćkowiak M
J Physiol Pharmacol; 2008 Jun; 59(2):229-38. PubMed ID: 18622042
[TBL] [Abstract][Full Text] [Related]
40. In vitro and in vivo characterization of F-97013-GD, a partial 5-HT1A agonist with antipsychotic- and antiparkinsonian-like properties.
Zazpe A; Artaiz I; Innerárity A; Del Olmo E; Castro E; Labeaga L; Pazos A; Orjales A
Neuropharmacology; 2006 Jul; 51(1):129-40. PubMed ID: 16643965
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
